Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

C-188-9 · TTI-101

Small molecule · Inhibitor of signal transducer and activator of transcription 3 (STAT3) · developed by Tvardi Therapeutics

Phase 1/2 Most advanced trial
TVRD Developer
1 Registered trials

What is C-188-9?

C-188-9 is an orally bioavailable binaphthol-sulfonamide inhibitor of STAT3. It binds the phosphotyrosyl peptide site in the SH2 domain of STAT3, blocking JAK-mediated tyrosine phosphorylation, nuclear translocation and promoter binding. It is studied in hepatocellular carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
TTI-101
Drug type
Small molecule
Targets
signal transducer and activator of transcription 3 (STAT3)
Mechanism
Inhibitor of signal transducer and activator of transcription 3 (STAT3)
Pathways
JAK/STAT3 signaling, STAT3 nuclear translocation and promoter binding
Therapy area
Oncology
Developer
Tvardi Therapeutics, Incorporated (TVRD)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
KZ3DLD11RQ

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05440708 Phase 1/2 Hepatocellular Carcinoma Recruiting TVRD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hepatocellular Carcinoma

Other drugs acting on STAT3

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the TVRD page.

Follow TVRD, the company behind C-188-9

See TVRD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TVRD catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.